We are building a pipeline of uniquely assembled, highly stable ADCs by leveraging proprietary conjugation, linker and payload technologies that enable us to utilize previously inaccessible targeting molecules and novel payloads. We are currently advancing three proprietary lead candidates in solid and hematological tumors targeting the most deadliest cancers globally. Our goal is to consolidate the knowledge gained over the last 20 years and translating it into meaningful therapeutic benefits to broaden the treatment horizon of ADCs.
